These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 25186974)
1. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor. Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974 [TBL] [Abstract][Full Text] [Related]
2. Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. Hoffmann K; Baqi Y; Morena MS; Glänzel M; Müller CE; von Kügelgen I J Pharmacol Exp Ther; 2009 Nov; 331(2):648-55. PubMed ID: 19690189 [TBL] [Abstract][Full Text] [Related]
3. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036 [TBL] [Abstract][Full Text] [Related]
4. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets. Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861 [TBL] [Abstract][Full Text] [Related]
5. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Aungraheeta R; Conibear A; Butler M; Kelly E; Nylander S; Mumford A; Mundell SJ Blood; 2016 Dec; 128(23):2717-2728. PubMed ID: 27694321 [TBL] [Abstract][Full Text] [Related]
6. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. VAN Giezen JJ; Nilsson L; Berntsson P; Wissing BM; Giordanetto F; Tomlinson W; Greasley PJ J Thromb Haemost; 2009 Sep; 7(9):1556-65. PubMed ID: 19552634 [TBL] [Abstract][Full Text] [Related]
7. Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y(12)-receptor. Hoffmann K; Sixel U; Di Pasquale F; von Kügelgen I Biochem Pharmacol; 2008 Nov; 76(10):1201-13. PubMed ID: 18809389 [TBL] [Abstract][Full Text] [Related]
9. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects. Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990 [TBL] [Abstract][Full Text] [Related]
10. Ticagrelor inverse agonist activity at the P2Y Khalil J; Dimofte T; Roberts T; Keith M; Amaradasa K; Hindle MS; Bancroft S; Hutchinson JL; Naseem K; Johnson T; Mundell SJ Br J Pharmacol; 2024 Jan; 181(1):21-35. PubMed ID: 37530222 [TBL] [Abstract][Full Text] [Related]
11. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949 [TBL] [Abstract][Full Text] [Related]
12. Effect of ticagrelor on endothelial calcium signalling and barrier function. Gündüz D; Tanislav C; Schlüter KD; Schulz R; Hamm C; Aslam M Thromb Haemost; 2017 Jan; 117(2):371-381. PubMed ID: 27904901 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents. Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677 [TBL] [Abstract][Full Text] [Related]
14. Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions. Rauch BH; Rosenkranz AC; Ermler S; Böhm A; Driessen J; Fischer JW; Sugidachi A; Jakubowski JA; Schrör K Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2434-42. PubMed ID: 21071695 [TBL] [Abstract][Full Text] [Related]
15. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist. Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013 [TBL] [Abstract][Full Text] [Related]
16. Characterisation of P2Y(12) receptor responsiveness to cysteinyl leukotrienes. Foster HR; Fuerst E; Lee TH; Cousins DJ; Woszczek G PLoS One; 2013; 8(3):e58305. PubMed ID: 23472176 [TBL] [Abstract][Full Text] [Related]
17. Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. Chhatriwala M; Ravi RG; Patel RI; Boyer JL; Jacobson KA; Harden TK J Pharmacol Exp Ther; 2004 Dec; 311(3):1038-43. PubMed ID: 15345752 [TBL] [Abstract][Full Text] [Related]
18. The P2 receptors and congenital platelet function defects. Cattaneo M Semin Thromb Hemost; 2005 Apr; 31(2):168-73. PubMed ID: 15852220 [TBL] [Abstract][Full Text] [Related]
19. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426 [TBL] [Abstract][Full Text] [Related]
20. P2Y12 platelet receptors: importance in percutaneous coronary intervention. Falcão FJ; Carvalho L; Chan M; Alves CM; Carvalho AC; Caixeta AM Arq Bras Cardiol; 2013 Sep; 101(3):277-82. PubMed ID: 23917456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]